• Mashup Score: 0

    Pamela L. Kunz, MD, Yale University School of Medicine, New Haven, CT, talks on the challenging of managing endocrine tumors, including determination of treatment sequencing. Patients with low-grade or slow growing endocrine tumors tend to be treated with first-line somatostatin analogues, such as octreotide or lanreotide, with options expanding within the second-line treatment setting. Upcoming trials are utilizing comparator arms, including a Phase II trial (NCT05247905) comparing capecitabine plus temozolomide to lutetium Lu 177-dotatate in advanced pancreatic neuroendocrine tumors. Such trials enables comparison of active agents which has previously been lacking in the field. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

    Tweet Tweets with this article
    • 🎥@PamelaKunzMD of @YaleMedicine discusses challenges in endocrine tumor management and exciting upcoming trials to compare treatments: ➡️https://t.co/h6MLQMl3YL #PancSM #UroOnc #UroSoMe

  • Mashup Score: 0

    In this podcast we’ll hear from experts in GU cancer on some of the most exciting clinical trial data in…

    Tweet Tweets with this article
    • Did you know that September is Urological Cancer Awareness Month? 🤔 Listen to our podcast on #bladdercancer highlights from #ASCO23, including results from the THOR, NORSE, and RAGNAR trials! Give it a listen 👉 https://t.co/u7BaS4bwEo #Oncology #GUsm #PCsm #uroonc https://t.co/sy8RcPqdwM

  • Mashup Score: 0

    Anusha Chidharla, MBBS, University of Kansas Medical Center, Kansas City, MO, compares the real-world data of belzutifan in VHL-associated tumors versus clinical trial data. The objective response rate (ORR) for associated renal cell cancer was 23%, lower than the clinical trial’s 49%, likely due to shorter follow-up duration (8 months vs. 21 months) and less frequent scans. Safety findings were similar, with common side effects being anemia and fatigue (65-70%). Belzutifan dose was decreased in 30% of our patients (vs. 15% in the clinical trial) due to poorer performance status (ECOG 1-2 vs. ECOG 0). These results highlight the importance of longer follow-up and more frequent scans to capture treatment responses accurately in the real-world setting. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world

    Tweet Tweets with this article
    • 🎥Anusha Chidharla, MBBS, of @KUMedCenter presents real-world data on belzutifan in VHL-associated tumors, highlighting the need for longer follow-up and more scans for accurate treatment assessment: ➡️https://t.co/krZX6On1k4 #ASCO23 #UroOnc #UroSoMe

  • Mashup Score: 0

    The Video Journal of Oncology (VJOncology) is an independent, global, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve the awareness and understanding of oncology

    Tweet Tweets with this article
    • 📣 September is Urological Cancer Awareness Month Check out https://t.co/ys1d8pDAKO to see our extensive coverage of #GUCancer, such as our interview with @PBarataMD on future approaches in #prostatecancer 🎥 👉 https://t.co/ypRuITaSTL #Oncology #GUsm #PCsm #uroonc https://t.co/W1odu87TsU

  • Mashup Score: 1

    Pedro Barata, MD, University Hospitals Seidman Cancer Center, Cleveland, OH, provides important updates in genitourinary cancer at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress, including findings from the PEACE-1 trial (NCT01957436), as well as updates in PARP inhibitors with radioligands in prostate cancer. Dr Barata additionally comments on trials assessing salvage chemotherapy in renal cell carcinoma (RCC) and targeting EGFR in bladder cancer. This interview took place at the ASCO 2023 Annual Congress in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

    Tweet Tweets with this article
    • Did you know that September is Urological Cancer Awareness Month? 🤔 Check out this interview from our #GUCancer channel with @PBarataMD, where he discusses highlights in #genitourinarycancer at #ASCO23 👉 https://t.co/QELNE442c5 #GUsm #PCsm #uroonc https://t.co/ZMRsMXHdJd

  • Mashup Score: 0

    The Video Journal of Oncology (VJOncology) is an independent, global, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve the awareness and understanding of oncology

    Tweet Tweets with this article
    • 📣 September is Urological Cancer Awareness Month! Check out https://t.co/ys1d8pDAKO to see our extensive coverage of #GUCancer, such as our interview with @RavimadanDr on #prostatecancer during #ASCO23 👉 https://t.co/2n9pL8SB1C #GUsm #PCsm #uroonc https://t.co/8zrlL0Nn6U

  • Mashup Score: 0

    David A. Braun, MD, PhD, Yale School of Medicine, New Haven, CT, explains how a transitional study used advanced genomic techniques, such as single cell approaches, to uncover the causes of resistance to anti-PD1 therapy. Single cell RNA sequencing analysis from various clinical trial samples showed that slightly exhausted T-cells that expressed markers such as SLAMF7, were strongly linked with therapeutic resistance. This finding needs to be corroborated in other studies and requires functional testing, to uncover if this is a biomarker, predictive factor, or a component that can be modulated. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

    Tweet Tweets with this article
    • 🎥@BraunMDPhD of @YaleMed discusses using single-cell approaches to understand resistance to anti-PD1 therapy in kidney cancer. More research is needed to confirm its significance: ➡️https://t.co/Bg75pxiQKf⬅️ #ASCO23 #kcsm #UroOnc #UroSoMe

  • Mashup Score: 0

    Shilpa Gupta, MD, Cleveland Clinic, Cleveland, OH, talks on the trial design of the Phase III MAIN-CAV trial (NCT05092958) of maintenance cabozantinib and avelumab in patients with metastatic urothelial cancer. Based on the JAVELIN Bladder 100 trial (NCT02603432), maintenance avelumab is considered the standard of care in this setting, but responses remain poor in patients with certain metastases. The MAIN-CAV will assess the addition of cabozantinib in patients pre-treated with platinum-based chemotherapy, and overall survival will be the primary objective. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

    Tweet Tweets with this article
    • 🎥@shilpaonc (@ClevelndClinic) discusses the Phase III MAIN-CAV trial, aiming to improve outcomes for patients w/ metastatic UC via maintenance cabozantinib and avelumab: ➡️https://t.co/qMCOgJ49Dg⬅️ #ASCO23 #ImmunoOnc #CTSM #UroOnc #UroSoMe #BlcSM

  • Mashup Score: 0

    Daniel Petrylak, MD, Yale School of Medicine, New Haven, CT, comments on the changing field of urothelial cancer, including novel therapies such as enfortumab vedotin and erdafitinib, which have been assessed in the EV-103 trial (NCT03288545) and THOR (NCT03390504) trials, as well as sacituzumab govitecan. Treatment can depend on the FGFR status of patients, where erdafitinib has shown benefit in patients with FGFR alterations. Adverse events can additionally influence which drug a patient will receive. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

    Tweet Tweets with this article
    • 🎥@DanielPetrylak from @YaleMed discusses the evolving landscape of UC treatment, emphasizing the importance of patient-specific factors and FGFR status in guiding therapy decisions: ➡️https://t.co/5Rb8fCdTdT⬅️ #ASCO23 #BlcSM #UroOnc #UroSoMe #ImmunoOnc